[Form 3] SOPHiA GENETICS SA Initial Statement of Beneficial Ownership
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief Executive Officer Camblong Jurgi has filed a Form 3 reporting his initial ownership in the company. He directly holds 3,307,325 ordinary shares, including 616,351 ordinary shares issuable upon settlement of restricted stock units that vest over time, and 891,320 ordinary shares have been pledged under lending arrangements. He also reports several share options giving rights to buy additional ordinary shares at exercise prices ranging from 3.1600 to 18.0000 per share, with expirations between late 2028 and early 2035. Certain option and RSU awards vest in scheduled monthly or quarterly installments through 2028.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Camblong Jurgi
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 100,000 shares (Direct);
Ordinary Shares — 3,307,325 shares (Direct)
Footnotes (1)
- Includes 616,351 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 19,938 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 223,215 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 145,575 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 227,623 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027. 891,320 ordinary shares have been pledged pursuant to lending arrangements. The share options are fully vested and exercisable. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.
FAQ
What does Camblong Jurgi report owning in SOPH on this Form 3?
Camblong Jurgi reports direct ownership of 3,307,325 SOPHiA GENETICS ordinary shares. This total includes 616,351 shares issuable upon vesting of restricted stock units and shares that have been pledged under lending arrangements.
What stock options does the SOPHiA GENETICS CEO report holding on Form 3?
Camblong Jurgi reports multiple share options to buy SOPHiA GENETICS ordinary shares. These options have exercise prices ranging from 3.1600 to 18.0000 per share and expiration dates from November 2028 through April 2035, with some already fully vested and others vesting over time.
How do the CEO’s SOPH restricted stock units vest over time?
The Form 3 footnotes describe four RSU grants vesting monthly or quarterly through April 2, 2028. One grant also has 50% vesting on April 2, 2026, with the remaining units vesting in equal quarterly installments through April 2, 2027, conditioned on continued service.